⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL129804 | 0.84 | PDPK1 (0.37) | — | |
| Purine SCHEMBL3021752 | 0.82 | KDM4A (0.36) | — | |
| Purine SCHEMBL6421376 | 0.82 | KDM4A (0.38) | — | |
| Purine SCHEMBL2120547 | 0.82 | KDM4A (0.38) | — | |
| Purine SCHEMBL3157 | 0.82 | — | — | |
| Purine SCHEMBL29456595 | 0.82 | — | — | |
| Adenine SCHEMBL844753 | 0.82 | PI4KA (0.37) | — | |
| Mercaptopurine Anhydrous SCHEMBL7199288 | 0.81 | — | — | |
| Purine SCHEMBL6959949 | 0.81 | CHEK1 (0.33) | — | |
| Purine SCHEMBL6438162 | 0.80 | KDM4A (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3478325-B1 | ELIMINATION OF PROLIFERATING CELLS FROM STEM CELL-DERIVED GRAFTS | RES FOUND DEV (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-118355023-A | Method for producing therapeutic immune cells with enhanced metabolic adaptation and compositions thereof | 得克萨斯大学体系董事会 | 2024-07-16 | — | — | CN | disclosed |
| EP-4392061-A1 | CD3 EPSILON CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF | The Regents of the University of Colorado, a body corporate (US) | 2024-07-03 | — | — | EP | disclosed |
| CN-118265535-A | Engineered NK cells with optimally signaling CAR constructs | 得克萨斯大学体系董事会 | 2024-06-28 | — | — | CN | disclosed |
| WO-2024137789-A2 | CD3 AND ITCR EXPRESSING ENGINEERED NATURAL KILLER CELLS WITH ENHANCED FUNCTION FOR ADOPTIVE IMMUNOTHERAPY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-06-27 | — | — | WO | disclosed |
| CN-118251227-A | Antibody-loaded immune cells and methods for cancer treatment | 得克萨斯大学体系董事会 | 2024-06-25 | — | — | CN | disclosed |
| CN-118234744-A | Chimeric antigen receptor targeting HLA-G positive cancers | 得克萨斯大学体系董事会 | 2024-06-21 | — | — | CN | disclosed |
| US-20240189357-A1 | CHIMERIC ANTIGEN RECEPTORS TO TARGET CD5-POSITIVE CANCERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-06-13 | — | — | US | disclosed |
| EP-4380967-A1 | LAT ACTIVATING CHIMERIC ANTIGEN RECEPTOR T CELLS AND METHODS OF USE THEREOF | The Regents of the University of Colorado, a body corporate (US) | 2024-06-12 | — | — | EP | disclosed |
| CN-118119643-A | BCMA targeting compositions and methods of use thereof | 武田药品工业株式会社 | 2024-05-31 | — | — | CN | disclosed |
| WO-2003012049-A2 | METHODS AND COMPOSITION CONCERNING HERPES VIRUS US3 AND BAD-INVOLVED APOPTOSIS | UNIVERSITY OF CHICAGO (US) | 2003-02-13 | — | — | WO | disclosed |
| WO-2003007889-A2 | THERAPEUTIC AGENTS COMPRISING PRO-APOPTOTIC PROTEINS | RESEARCH DEVELOPMENT FOUNDATION (US) | 2003-01-30 | — | — | WO | disclosed |
| US-20020143062-A1 | Method to incorporate N-(4-hydroxyphenyl) retinamide in liposomes | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2002-10-03 | — | — | US | disclosed |
| WO-2001025255-A9 | NOVEL ZINC FINGER PROTEIN | BAYLOR COLLEGE MEDICINE (US) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002069886-A2 | MODIFIED PROTEINS, DESIGNER TOXINS, AND METHODS OF MAKING THEREOF | RESEARCH DEVELOPMENT FOUNDATION (US) | 2002-09-12 | — | — | WO | disclosed |
| WO-2002041871-A2 | COMPOSITION COMPRISING AN IMEXON OR DERIVATIVES THEREOF AND LIPIDS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2002-05-30 | — | — | WO | disclosed |
| WO-2002032413-A2 | A METHOD TO INCORPORATE N-(4-HYDROXYPHENYL) RETINAMIDE IN LIPOSOMES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2002-04-25 | — | — | WO | disclosed |
| EP-1180016-A2 | METHODS AND COMPOSITIONS FOR NON-VIRAL GENE THERAPY FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES | Introgen Therapeutics, Inc. (US) | 2002-02-20 | — | — | EP | disclosed |
| WO-2001025255-A2 | NOVEL ZINC FINGER PROTEIN | BAYLOR COLLEGE OF MEDICINE (US) | 2001-04-12 | — | — | WO | disclosed |
| WO-2000071096-A2 | METHODS AND COMPOSITIONS FOR NON-VIRAL GENE THERAPY FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES | INTROGEN THERAPEUTICS, INC. (US) | 2000-11-30 | — | — | WO | disclosed |